Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

69 Press Releases
DateTitleCompany
27 Jul 16 CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
26 Jul 16 CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
22 Jul 16 CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation CSL Plasma ,
Published by
PharmiWeb.com
21 Jul 16 CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress CSL Behring ,
Published by
PharmiWeb.com
19 Jul 16 CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress CSL Behring,
Published by
PR Newswire
18 Jul 16 U.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE) CSL Behring,
Published by
PR Newswire
29 Jun 16 CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 CSL Behring ,
Published by
PharmiWeb.com
29 Jun 16 CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A CSL Behring ,
Published by
PharmiWeb.com
28 Apr 16 CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions CSL Behring ,
Published by
PharmiWeb.com
19 Apr 16 CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia CSL Behring ,
Published by
PharmiWeb.com
19 Mar 16 CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies CSL Behring ,
Published by
PharmiWeb.com
09 Mar 16 CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives CSL Behring,
Published by
PR Newswire
25 Feb 16 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia CSL Behring,
Published by
PharmiWeb.com
04 Feb 16 CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S. CSL Behring ,
Published by
PharmiWeb.com
22 Dec 15 CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
22 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring ,
Published by
PharmiWeb.com
21 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring,
Published by
PR Newswire
21 Dec 15 CSL CEO Says Corporate Responsibility And Sustainability Are All About Continuous Improvement CSL Limited,
Published by
PharmiWeb.com
02 Dec 15 CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition CSL Behring,
Published by
PR Newswire
10 Dec 15 CSL Behring Expands Operations to Russia CSL Behring ,
Published by
PharmiWeb.com
01 Dec 15 CSL opens UK Seqirus office CSL Limited Seqirus,
Published by
Ruder Finn UK for Seqirus
16 Nov 15 CSL brands world's no. 2 influenza vaccine provider as Seqirus CSL ,
Published by
PharmiWeb.com
07 Dec 15 CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition CSL Behring,
Published by
PR Newswire
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring,
Published by
PR Newswire
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring ,
Published by
Pharmiweb.com
25 Aug 15 CSL Behring Receives Marketing Authorization for Respreeza® in Europe CSL Behring ,
Published by
Pharmiweb.com
28 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
29 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring ,
Published by
PharmiWeb.com
17 Sep 15 CSL Plasma Donates 60 Bicycles To Boys And Girls Club, Broward County CSL Plasma Inc.,
Published by
PR Newswire
10 Sep 15 Centers for Medicare and Medicaid Services Extends New Technology Add-On Payment for CSL Behring’s Kcentra® for Third Year CSL Behring ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.